|
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
RECRUITINGPhase 3Sponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
PhasePhase 3
SponsorAssistance Publique - Hôpitaux de Paris
Started2023-07-07
Est. completion2031-07-07
Eligibility
Age60 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05387954
Summary
To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80 years with a PFO with large shunt (\> 20 microbubbles) or a PFO associated with an ASA (\> 10 mm), and an otherwise unexplained ischemic stroke.
Eligibility
Age: 60 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria: * Man or woman aged 60 to 80 years. * Recent (≤ 6 months) ischemic stroke confirmed by cerebral imaging regardless of symptom duration. * Absence of a more probable cause of stroke than PFO after a standardized etiological work-up (see addenda). * Presence of a PFO with at least 1 of the 2 following characteristics: * PFO with large shunt \> 20 microbubbles appearing in the left atrium during at least one of the 3 cardiac cycles after opacification of the right atrium, detected spontaneously or during provocative manoeuvers, on contrast transthoracic (TTE) or transoesophageal (TOE) echocardiography. The diagnosis of PFO by contrast TEE must be confirmed by contrast TOE showing a right-to-left passage of the contrast material across the PFO. * PFO with ASA on transoesophageal echocardiography: excursion \>10 mm * Affiliation to a French Health Insurance system. Informed consent. Exclusion Criteria: * Life expectancy \< 4 years. * Contraindication to both experimental treatments (PFO closure, oral anticoagulant therapy) or to the reference treatment (antiplatelet therapy) (see paragraph 20.5). * Indication to long-term anticoagulant therapy. * mRS \>= 3. * Presence of other medical conditions that would lead to inability to complete the study or interfere with the assessment of outcomes. * Previous surgical or transcatheter treatment of PFO or ASA. Expected impossible follow-up or poor compliance. * Patient unable to understand the informed consent form. Patient under tutorship, curatorship, or legal protection.
Conditions3
Cryptogenic Ischemic StrokeHeart DiseasePatent Foramen Ovale
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorAssistance Publique - Hôpitaux de Paris
Started2023-07-07
Est. completion2031-07-07
Eligibility
Age60 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05387954